The PVA Summit and Expo 2024 will focus on the novel concepts, treatments, strategies, and methods to promote excellence and achieve state of the art healthcare for veterans and others living with spinal cord injuries and dysfunctions, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.
The mission of the PVA Summit and Expo 2024 is to bring together professionals across the continuum of care who are treating individuals living with spinal cord injury (SCI) and dysfunction, multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) to share new clinical information, research data and innovative initiatives to improve care and support clinicians in maintaining their specialty certification and/or license to practice.
Advance interdisciplinary care and innovate healthcare models for SCI, MS, and ALS patients:
To enhance, advance, and improve interdisciplinary care across the lifespan of individuals living with SCI, MS, and ALS.
To expand and promote evidence-based medicine and the knowledge about SCI, MS, and ALS conditions.
To identify cutting edge research priorities in SCI, MS, and ALS and present data on new developments in assessment, treatment, and health policy.
PVA Summit + Expo 2024 provides an interdisciplinary opportunity to network with healthcare professionals working across the continuum in spinal cord injury and disease care and treatment. Sessions are geared for healthcare providers including:
Abstracts are intended to represent clinical practice, research or health policy content related to spinal cord injury, multiple sclerosis, ALS, or other spinal cord disorders.
All submitted abstracts must meet CME/CEU accreditation standards to be approved for credit. Abstracts of presentations should be balanced and free of commercial bias. Commercial content, product endorsements, or service related advertisements are not permitted. Presentations by speakers with vested or fiduciary interest in product will not be accepted.
Topics should address clinical treatment, research, health policy or program development in the areas of:
Preconference Institute (on Sunday, August 25 only)
Presentations will be on clinical or research issues and will be 30 or 75 minutes in length, with an additional 15 minutes allotted for questions and discussion (total 45 or 90 minutes).
ADDITIONAL/ALTERNATE PRESENTERS MAY NOT BE ADDED AFTER ACCEPTANCE, EVEN IF REIMBURSEMENT IS NOT REQUESTED.
Information on all contributing authors may be included in the abstract submission; however, only the presenters will be listed in the Summit + Expo 2024 program.
The abstract should include a summary of information to be presented, including major themes, expanded version of learning objectives, outline of issues/subjects to be discussed, an overview of case studies, points to be illustrated, and principles to be discussed during the interactive session. 90-minute sessions and preconference institutes should include some interactive / audience involvement component.
Clinical Practice/Program Abstracts
A poster is a visually formatted presentation of a topic using charts, graphs, illustrations, and photographs to supplement a written narrative. The topic may be clinically, or research based, and describe new techniques, procedures, or technologies. It provides a visual forum for one‐to‐one discussion with the presenter.
Presenters will have the opportunity to discuss pertinent issues highlighted in the poster with attendees during the scheduled viewing sessions. Interactive viewing sessions, with presenter present, are scheduled during the PVA Summit + Expo 2024. Posters will be available for viewing throughout the meeting. Presenters must be present at the scheduled viewing session times, provided in the acceptance letter.
Clinical Practice/Program Abstracts
Please keep in mind that reference to equipment, devices, or pharmaceutical products must use the correct manufacturer, trade, and/or generic names; appropriate acknowledgements for financial support must be declared. In all cases, patient anonymity must be protected in accordance with the HIPAA Privacy Law. Please do not duplicate your abstract submission for two types of sessions (i.e., poster and platform). Only submit your abstract one time with the preferred session type selected.
The following criteria are used in determining abstract acceptance:
The topic is pertinent to the development of knowledge related to SCI/D, MS, ALS clinical practice and is relevant to the purpose and mission of the PVA Summit Symposium.
The abstract enhances the foundation for clinical decision-making or stimulates thinking about practice applications when caring for the SCI/D, MS or ALS patient.
Overall, the abstract is readable, accurately presented and conclusion is valid. The abstract is complete including all data collection. Spelling and grammar are correct.
The presentation demonstrates an insightful application or a creative and original solution to a clinical practice issue or problem caring for the patient with SCI/D, MS, or ALS.
All applicants will be notified of proposal acceptance by March 11, 2024. If you are unable to accept the session assignment, you must contact PVA by March 20, 2024 at Summit@pva.org.
Should a presenter be unable to make a presentation after acceptance of the assignment, please immediately contact Cheryl Vines at firstname.lastname@example.org or 202-256-5526.
Final PowerPoint slides of your presentation must be submitted, using the online system, on or before July 8, 2024.
PVA will provide the following reimbursement to help defray expenses for accepted session speaker(s):
Note: Travel reimbursements are by session, not speaker, if there is more than one speaker, the amount must be shared. It is up to the submitter to determine how these funds will be divided.
If you have program-related questions, please contact us at Summit@pva.org.
For technical assistance, please contact: AffinityCE technical support at email@example.com.